Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$2.19M-40.03%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric K. Olson
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 32
- Beta
- 0.59
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -48.88
Financials
Revenue
$2.19M-40.0%Net Income
$-1.59MEBITDA
$-1.59MFree Cash Flow
$-1.51MEPS (diluted)
$-0.24Shares Outstanding (diluted)
6.67M+876995.5%Operating Expenses
$2.94MCash & Debt
$2.00MReturn of Capital
$926.0KRevenue by Segment (annual)
$1.02MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.02M | $-17.08M | $-6.16 |
| 2024 | $1.25M | $-11.02M | $-14.87 |
| 2023 | $2.63M | $-8.26M | $-35.43 |
| 2022 | $601.0K | $-12.04M | $-54.67 |
| 2021 | $606.0K | $-9.31M | $-47.59 |
| 2020 | $594.0K | $-7.03M | $-44.57 |
| 2019 | $689.0K | $-4.80M | $-311.65 |
| 2018 | $95.0K | $-8.65M | $-2373.00 |
| 2017 | $11.23M | $-9.33M | $-9395.07 |
| 2016 | $15.23M | $-16.60M | $-32255.41 |
| 2015 | $19.45M | $-23.91M | $-106750.00 |
| 2014 | $22.77M | $-32.58M | $-678791.67 |
| 2013 | $22.31M | $-8.29M | $-376636.36 |
| 2012 | $23.07M | $-35.03M | $-1592484.95 |
Valuation
SINThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·5d ago·Neutral
SINTX Strengthens Patent Portfolio to Support International Growth Across Healthcare Markets Two issued patents and three allowed applications support commercialization opportunities in orthopedic devices, biomaterials and medical textiles SALT LAKE CITY, Utah, Nov. 17, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced two paten…
View source ↗ - Newsglobenewswire.com·11d ago·Positive
SINTX Technologies Advances SiN/PEEK 3D Printing Platform Toward Personalized Orthopedic Implant Commercialization Company completes additive manufacturing facility buildout, advances proprietary silicon nitride–PEEK technology, expands leadership and targets initial product availability in 2027
View source ↗ - Newsseekingalpha.com·16d ago·Neutral
Sintx Technologies, Inc. (SINT) Q3 2026 Earnings Call Prepared Remarks Transcript Sintx Technologies, Inc. ( SINT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kevin Ontiveros - Chief Legal Officer Eric Olson - CEO & Chairman of the Board Kevin Trask - Chief Financial Officer Presentation Operator [Operator Instructions] As a reminder, today's call is being recorded. I would now like to turn the call over to SINTX Technologies Chief Legal Officer, Kevin Ontiveros.
View source ↗ - Newsglobenewswire.com·17d ago·Negative
SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon nitride technologies
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast SALT LAKE CITY, Utah, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced that it will release its third quarter 2026 financial results on Thursday, November 5, 2026, after the market close. The Company will also host a conference call and webcast …
View source ↗ - Newszacks.com·45d ago·Positive
What Makes SINTX TECHNOLOGIES (SINT) a New Buy Stock SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsglobenewswire.com·52d ago·Negative
SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone also enables Company to call Class B warrants SALT LAKE CITY, Utah, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics…
View source ↗ - Newsglobenewswire.com·69d ago·Negative
SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts Experts in implant retrieval, biomaterials and clinical practice examine the science, clinical experience and potential advantages of silicon nitride relative to established implant materials in Company-sponsored Orthopedics This Week Masterclass SALT LAKE CITY, Utah, Sept. 14, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials …
View source ↗ - Newszacks.com·95d ago·Positive
SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·103d ago·Neutral
Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript
View source ↗
Earnings
Fri, Mar 19(in 4 months)
Consensus estimate $-0.35 per share
Typical surprise -6.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.24 vs $-0.31beat
- Tue, Aug 11$-0.75 vs $-0.73miss
- Fri, May 15$-0.70 vs $-0.66miss
- Wed, Mar 18$-0.56 vs $-0.55miss
- Wed, Nov 12$-3.46 vs $-0.55miss
- Thu, Aug 14$-0.91 vs $-0.79miss
Estimates and results for SINT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SINT officers and directors.
- Bought
- $729k
- Sold
- $3k
52 trades
2 trades
- Lyons Christopher Michaelbought
- Lyons Christopher Michaelbought
- Moyes Jay Mbought
- Anderson Mark Lewisbought
- Honigblum Gregg R.bought
- Honigblum Gregg R.bought
- Honigblum Gregg R.bought
- Honigblum Gregg R.bought
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SINT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
